Fig. 1
From: Hsa-miR-335 regulates cardiac mesoderm and progenitor cell differentiation
Characterization of hESC-derived cardiomyocyte. a Schematic description of cardiomyocyte differentiation protocol. Activin A and BMP4 compounds were used to induce differentiation of hESCs into mesoderm. Then, WNT inhibitor reagent (IWP2) was used to induce cardiac progenitor cell development followed by cardiomyocyte formation. b Time-dependent expression of NANOG (pluripotency marker), BRACHYURY (mesoderm marker), NKX2-5, ISL1 (cardiac progenitor cell markers), TNNT2, and MYH6 (cardiomyocyte markers) during the cardiac differentiation process. RT-qPCR data are presented as mean ± SEM normalized against day 0 data, for n = 3 independent experiments. GAPDH was used as a housekeeping gene. c Flow cytometry results confirmed the expression of BRACHYURY (day 1.5), NKX2-5 (day 5), and MYH6 (day 12) during the differentiation process. d Immunocytochemistry analysis of OCT4 (pluripotent hESCs) and MYH6 (cardiomyocytes) revealed the stemness potency of hESCs and successful differentiation of cardiomyocyte. Differentiated cardiomyocytes are shown in two magnitudes